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More recently, the NHS has introduced measures of quality which relate to targets in the patient's charter and are based, primarily, on measuring not how much is done but how fast it is done -that is, waiting times.
Challenging the notion that "faster is better" The issue of waiting times was analysed recently by Frankel and West,4 who showed that waiting times should not necessarily be seen as some expression of global deficiencies of the NHS. Firstly, they are made up of a rather small number of procedures; secondly, they are a relatively small percentage of the total throughput; and, lastly, a simple league table takes no account of the severity of the condition of people on waiting lists and the relative benefit they stand to gain from treatment.
More worrying than the actual aggregate time spent waiting for procedures is that some of the procedures people are waiting considerable times for are relatively cheaper and more cost effective at increasing quality of life (for example, hip replacements and cataract surgery) than many procedures for which there is little waiting. Improving this aspect of quality lies not in some blanket target for waiting time but redistributing resources away from those procedures which are less cost effective or whose impact on health is less. A sizable part of the waiting list may comprise people waiting for inappropriate treatments; it is even more worrying to think that the process of propelling patients even more rapidly towards unnecessary treatment will be interpreted as a quality improvement.
The targeting of waiting times as a measure of quality fails on at least three counts: * Distinguishing between inefficiency and excess "legitimate" demand * Considering the relative ability to benefit different client groups * On a more practical level it will produce a range of unintended consequences resulting from agents attempting to play the system and manipulate data. Thus waiting times are likely to be a rather poor proxy for quality in the NHS. Because something is easy to measure does not mean it is a good measure. This is not to argue against comparative waiting list data being available, since the results can usefully promote constructive discussion which generates important insights about the functioning of the service and ways that it can be improved.
The "bottom line" in health care A simple, though not comprehensive, breakdown of the attributes of quality which can be used for assessment includes access to, continuity of, comprehensiveness of, effectiveness of, and (more controversially) the efficiency of health care.' Efficiency is an important inclusion because if resources are not used efficiently, by implication some other allocation could produce more benefit with the same resources.
This paper concentrates on the issue of effectiveness and appropriateness, primarily because they may justifiably be regarded as the "bottom line" in health care However, the market is already being flooded with poor quality guidelines which have not been developed according to scientific criteria and are not based on rigorous reviews of the literature. It often seems as though professional groups see the development of guidelines as good in itself -and even as a way to protect professional interests by simply validating existing practice. The work of Grimshaw and Russell points to the ability of guidelines to change clinical practice': we must ensure that it is changed in the right way. Given the difficulty in changing professional behaviour, our energies should be devoted to those areas of clinical practice where good evidence exists that change will be worthwhile -in that there is good published evidence (from randomised controlled trials) for or against particular healthcare interventions and there is sufficient evidence that professional behavour significantly diverges from best practice, taking into account the consistent need for professional judgements deviating from guidelines, owing to the heterogeneity of the patient population.
UTILISATION REVIEW
In order to identify better where efforts should be concentrated and how this should be monitored the practice of utilisation review should be introduced, as a complement to guidelines and as part of quality initiatives of providers and purchasers. Utilisation review is (usually) a review of the case notes of patients with reference to a set of defined criteria, indicating the degree to which (allowing for the inevitable uncertainties in health care) procedures were appropriate to the health care needs of the patient and the extent that guidelines, if in place, are being adhered to There has been considerable debate about comparing patient outcomes (for example, mortality) between providers. The fundamental problem is that like is usually not being compared with like: patients are not randomly assigned to hospitals, clinicians, or treatments, and thus differences in outcomes over time or between providers are difficult to interpret since they are affected by differences in case mix. Providers dealing with the more severe cases may seem to be performing least well.'7 The key challenge is to disentangle the effects of case mix from those of providers in order to attribute cause, and this requires adjusting the outcomes for differences in severity or patient mix."' Statistical adjustment of observational data to remove the confounding effect of case mix is difficult because we may not know the important factors affecting prognosis and the data needed to make such an adjustment are unlikely to be routinely available or are often poorly coded.'9 Given these caveats, however, it does not make sense to compare waiting times, which are also sensitive to differences in variables like severity, throughput, and demand and are a much weaker measure of quality, while ignoring what may be significant variation in mortality rates or other health status measures.
If adjustment for case mix and the accuracy of data are adequate, comparisons may be used to identify statistically significant outliers, and these can be investigated for evidence of significant deficits in quality of care. For example, Hannan et al identified significant outlier hospitals providing open heart surgery after adjusting for several key variables and found during site visits that poor performers had problems with quality.20 This demonstrates the importance of supplementing the calculation and comparison of risk-adjusted mortality rates with reviews of actual care before drawing any conclusions about the effectiveness of care. 2' There are a few such examples in Britain in which the results have been used to inform contracting. For example, data on treatment and outcome for men with non-seminomatous germ cell (testicular) tumours were used in Scotland after adjustment using validated adjustment factors to examine variations in survival. The death rate in the one specialist unit in western Scotland was found to be significantly lower than the rates in the other four units grouped together.22 The nonspecialist units had nearly three times the death rate of the specialist one (p< 0001), and as a result the local health board modified its contracting decisions accordingly. Similar work is also being conducted on the treatment of colorectal cancer.
These methods of analysis which examine provider outcomes have several attractions compared to other approaches. Firstly, they allow first approximate evaluations of the quality of packages of care rather than just the individual treatments. Secondly, they may facilitate the identification of collateral factors such as volume and skills, which affect quality over and above the actual treatment given. This is important because clinical trials have not been used to examine these factors. This touches on the general area of the relation between the volume of activity and quality of care. Though most of the studies are observational, using routine data, there is considerable evidence that patients treated by clinicians and units carrying out procedures (for example, coronary artery bypass grafts) frequently have better outcomes than those treated by low volume providers. 23 In summary, though the notion of "quality of care" has become fashionable, most of the focus has been on initiatives such as the patient's charter, waiting times, quality of the physical environment, patient centredness in outcomes measurement, etc. Nevertheless, at the heart of quality must be the effectiveness and cost effectiveness of interventions. Without ensuring that health technologies are effective and are delivered appropriately then many of the other dimensions of quality may simply be window dressing. Substantial variations in the rates of procedures, the way in which similar patients are treated, and the degree to which professionals often ignore the best scientific evidence have all been well documented. The NHS needs methods for ensuring that the effectiveness dimension of quality is brought to the fore and becomes a routine part of quality assessment and activity. Clinical autonomy can no longer be an excuse for inappropriate care. The challenge for the future is twofold: to increase the amount of health technology assessment carried out and to develop methods of ensuring that health care converges with this best practice -that is, the promotion of evidence based practice. By introducing evidence based clinical guidelines and associated utilisation review and persuading purchasers to "purchase protocols" rather than just procedures the effectiveness dimension may become more routine, but it will require a radical rethink of the type of data collected and the way in which the purchaser provider split is managed.
